Syed Rizwanuddin Ahmad, MD, MPH, FISPE, FCP
Consultant/Associate Professor (adjunct), Rutgers School of Public Health, NJ, USA. Assistant Professor (adjunct) Georgetown University School of Medicine, Washington, DC, USA.
Email: drugsafetyconsultant@gmail.com
www.drugsafetyconsultant.com

Dr. Ahmad has adjunct academic appointments at Rutgers School of Public Health NJ, USA and Georgetown University School of Medicine, Washington, DC, USA. He is a pharmacovigilance and regulatory system strengthening consultant trained in pharmacovigilance, pharmacoepidemiology, drug regulatory science and clinical pharmacology with over 25 years of work experience at the U.S. Food and Drug Administration (FDA), United States Pharmacopeia (USP), and non-profit groups.

Dr. Ahmad consults in drug regulatory science, pharmacovigilance, pharmacoepidemiology, and regulatory affairs; on issues related to product safety (drugs; vaccines; herbals/dietary supplements); product quality; product approval; benefit-risk assessment; risk management plans; risk communication; access to medicines; generic drugs; poison and drug information center; medication errors; medicines policy; essential medicines; rational use of medicines; antimicrobial resistance; and global health. Areas of interest include active pharmacovigilance (cohort event monitoring) and anti-tuberculosis – TB/HIV/AIDS/malaria drugs; causality assessment; signal identification, detection and management; training, capacity building in pharmacovigilance and strengthening of FDA-like agencies in resource-limited countries. As a USAID/MSH, UNDP, SIDA, UNITAID/MSF and the WHO consultant, Dr. Ahmad has provided technical assistance to national medicines regulatory agencies/Ministries of Health and/or academia in several countries in Asia and Africa. He has been invited to give lectures/workshops in several international meetings.

For 15 years (1998-2013), he worked for the U.S. FDA, and served as a consultant to the review divisions of the Center for Drug and Evaluation and Research (CDER) and reviewed safety data in the pre- and the postmarketing phases of drug development and helped the Agency make informed decisions regarding drug approval, benefit-risk assessment, risk management plans, and risk communication. He has analyzed data from a wide and complex range of sources and produced clear scientific reviews/reports that have assessed the safety and effectiveness of several FDA regulated products. On several occasions, he has synthesized the recommendations from his reviews into plain language that has shaped the final labeling of the products and has been used for wider dissemination such as in the Agency's Drug safety communications. At the FDA, he was an active member of the Committee on Advanced Scientific Education (CASE) whose mission is to promote excellence in advanced scientific education, and assist FDA reviewers to maintain a high level of competency in regulatory and scientific knowledge. As a member of the CASE, he has organized seminars; workshops; courses and training sessions for FDA scientists. He was instrumental in the launch of CDER's first Epidemiology for Non-Epidemiologist course. While at the FDA, he was the scientific lead of several projects involving collaboration with various disciplines within and outside the Agency. He has extensive experience of collaboration with stakeholders in the academia, foreign regulatory agencies, industry, non-profits and civil society groups. He has organized/chaired and/or spoken at symposia/sessions in professional meetings (ISPE, DIA, ISoP, ASCPT) on cutting edge issues in drug safety and risk management with thought leaders from the FDA, EMA, MHRA, ANSM, MPA, PMDA, TGA, academia and industry. He is a recipient of a number of FDA Awards and Commissioner's citations. He has been invited to give lectures/workshops at several international meetings.

Dr. Ahmad attended the inaugural ICPE in 1989 where the International Society for Pharmacoepidemiology (ISPE) was born. During his more than 25 years of membership, he reviewed abstracts for the annual ICPE meetings; served as a member of several Committees (Education; Publication; and Global Development); served as a Chair; and Vice Chair of the Government and Regulatory Council; edited ISPE's newsletter Scribe; organized/chaired/moderated several symposia/sessions during annual meetings; served on the faculty of introduction to pharmacoepidemiology course and has given introduction to pharmacovigilance lectures. In 2014, he conceived the idea for the first Vaccine Safety pre-conference course with the support of Vaccine SIG that was offered in ICPE Boston in August 2015; at ICPE Dublin in August 2016; and will be offered at ICPE Montreal in August 2017. In 2006, in recognition of his contributions, he was inducted as a Fellow in ISPE (FISPE). In 2009, he was conferred Fellowship of the American College of Clinical Pharmacology (FCP).

He has several publications to his credit including 5 book chapters on spontaneous reporting/pharmacovigilance; and a chapter on FDA evolution of drug approval process.